NASDAQ:VICL

Vical (VICL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.68
$3.15
52-Week Range
N/A
Volume
35,024 shs
Average Volume
1.44 million shs
Market Capitalization
$21.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VICL stock logo

About Vical Stock (NASDAQ:VICL)

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

VICL Stock News Headlines

This song is our story
See More Headlines
Receive VICL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/19/2019
Today
5/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VICL
CUSIP
92560210
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-16,250,000.00
Net Margins
-1,002.10%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.62 million
Book Value
$1.82 per share

Miscellaneous

Free Float
N/A
Market Cap
$21.01 million
Optionable
Not Optionable
Beta
0.32
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Vijay B. Samant (Age 66)
    CEO, Pres & Director
  • Dr. Lawrence Russell Smith (Age 58)
    Sr. VP of Research
  • Mr. Anthony Alan Ramos (Age 52)
    VP, CFO & Chief Accounting Officer
  • Dr. Mammen P. Mammen Jr. (Age 55)
    Former Sr. VP of Clinical Devel.

VICL Stock Analysis - Frequently Asked Questions

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) issued its earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.17). The biotechnology company earned $0.12 million during the quarter, compared to analysts' expectations of $0.04 million. Vical had a negative trailing twelve-month return on equity of 29.46% and a negative net margin of 1,002.10%.

What other stocks do shareholders of Vical own?
This page (NASDAQ:VICL) was last updated on 5/14/2024 by MarketBeat.com Staff

From Our Partners